Replies to post #142426 on Biotech Values

[p3analyze]

>>expected little bit better HCC data<<
Which data point in the asco abstract do you think analysts expected more than from the Jan press release?

except from January 17, 2012
ArQule Announces Tivantinib Meets Primary Endpoint, Significantly Extending Time to Progression in Phase 2 Trial in Second-Line Hepatocellular Carcinoma
WOBURN, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) today announced that treatment with tivantinib as single agent therapy produced a statistically significant 56 percent improvement in time-to-progression (TTP) in the intent-to-treat (ITT) population, the primary endpoint in a randomized, controlled Phase 2 clinical trial in previously treated patients with hepatocellular carcinoma (HCC) (hazard ratio = 0.64; log rank p-value = 0.04).

excerpt from asco abstract

http://abstract.asco.org/AbstView_114_95738.html

Median: T arm P arm HR CI* Log-rank p value
TTP (mos)
ITT 1.6 1.4 0.64 0.43-0.94 0.04
Met + 2.9 1.5 0.43 0.19-0.97 0.03
PFS (mos)
ITT 1.7 1.5 0.67 0.44-1.04 0.06
Met + 2.4 1.5 0.45 0.21-0.95 0.02
*90%CI for primary TTP. 95%CI for other endpoints.